Psychodynamic psychotherapy and clomipramine in the treatment of major depression.
OBJECTIVE
The authors compared a combination of clomipramine and psychodynamic psychotherapy with clomipramine alone in a randomized controlled trial among patients with major depression.


METHODS
Seventy-four patients between the ages of 20 and 65 years who were assigned to ten weeks of acute outpatient treatment for major depression were studied. Bipolar disorder, psychotic symptoms, severe substance dependence, organic disorder, past intolerance to clomipramine, and mental retardation were exclusion criteria.


RESULTS
Marked improvement was noted in both treatment groups. Combined treatment was associated with less treatment failure and better work adjustment at ten weeks and with better global functioning and lower hospitalization rates at discharge. A cost savings of 2,311 dollars per patient in the combined treatment group, associated with lower rates of hospitalization and fewer lost work days, exceeded the expenditures related to providing psychotherapy.


CONCLUSIONS
Provision of supplemental psychodynamic psychotherapy to patients with major depression who are receiving antidepressant medication is cost-effective.
Burnand
Yvonne
Y
University of Geneva Psychiatric Center, Switzerland. yvonne.burnand@hcuge.ch
Andreoli
Antonio
A
Kolatte
Evelyne
E
Venturini
Aurora
A
Rosset
Nicole
N
D000328:Adult; D000368:Aged; D001364:Awareness; D002997:Clomipramine / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000191:economics / Q000628:therapy*; D004645:Empathy; D005260:Female; D006801:Humans; D007398:Interpersonal Relations; D008297:Male; D008875:Middle Aged; D011613:Psychotherapy / Q000191:economics / Q000379:methods*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome
D002997:Clomipramine; D017367:Selective Serotonin Reuptake Inhibitors